Dare Bioscience (DARE) Operating Margin (2016 - 2026)

Dare Bioscience (DARE) has reported Operating Margin for 7 consecutive years, with 1582.53% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Margin fell 1966207.0% year-over-year to 1582.53%; the trailing twelve-month figure through Jun 2026 stood at 1001.35% (down 10539355.0% YoY), and the FY2025 full-year result was 1315.51%, up 23837669.0% from the prior year.
• Operating Margin fell to 1582.53% in Q2 2026 per DARE's latest filing, from 143.72% in the prior quarter.
• Across five years, Operating Margin topped out at 18079.54% in Q2 2025 and bottomed at 162340.76% in Q3 2025.
• Historically, Operating Margin has averaged 22119.33% across 5 years, with a median of 1211.09% in 2023.
• The widest YoY moves for Operating Margin: up 5087866 bps in 2025, down 15111208 bps in 2025.
• Over 5 years, Operating Margin stood at 3.84% in 2022, then plunged by 7543 bps to 286.05% in 2023, then soared by 3060 bps to 8465.75% in 2024, then plunged by 102 bps to 143.72% in 2025, then slumped by 1001 bps to 1582.53% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 1582.53%, 143.72%, and 162340.76% for Q2 2026, Q4 2025, and Q3 2025 respectively.